Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 222Neoplasms 193Prostatic Neoplasms 158Multiple Myeloma 139Neoplasm Metastasis 117Melanoma 110Colorectal Neoplasms 107Leukemia, Myeloid, Acute 102Lymphoma 99Lung Neoplasms 94Ovarian Neoplasms 85Squamous Cell Carcinoma of Head and Neck 75Lymphoma, Non-Hodgkin 74Leukemia, Lymphocytic, Chronic, B-Cell 70Pancreatic Neoplasms 64Triple Negative Breast Neoplasms 62Myelodysplastic Syndromes 61Parkinson Disease 4, Autosomal Dominant Lewy Body 60Hematologic Neoplasms 59Head and Neck Neoplasms 59Recurrence 56Glioblastoma 55Leukemia 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Sarcoma 49Brain Neoplasms 49Carcinoma, Hepatocellular 48Lymphoma, Large B-Cell, Diffuse 47Lymphoma, Follicular 46

Interventions

niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Castration-sensitive Prostate Cancer × 1 year × Clear all
NCT04497844 2026-06-05

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡